quote:

Biokloot schreef op 20 mei 2021 17:19:

Niet eventueel , het IS concurrentie.

quote:

Katsjinggg schreef op 20 mei 2021 17:46:

Mithra’s General Meeting of Shareholders Approves
the Renewal of its Board of Directors
Liege, Belgium, 20 May 2021 – 17:45 CEST – Mithra (Euronext Brussels: MITRA), a company
dedicated to Women’s Health, today held its Annual General Meeting of securities holders. All agenda
items put to vote were approved, including the appointment of Directors for a two-year-mandate.
The new Board of directors will count 10 directors with varied and complementary profiles, allowing
Mithra to have proven expertise in all the fields covering pharmaceutical products development. For
the first time, this board will have a perfect parity with 5 women directors and 5 men directors, as well
as 5 independent and 5 non-independent directors.
Parity and multidisciplinary expertise
Mr. Ajit Shetty will become Chairman of the Board in June, succeeding Ms. Patricia van Dijck (Market
Access & Public Affairs Director at GSK) who will remain on the Board as Independent Director.
Mr Shetty has served as Chairman of the Board of Janssen Pharmaceutica until 2012 and has led the
global supply chain at Johnson & Johnson, the world's number 1 healthcare company. Elected
Flanders Manager of the Year in 2004, Ajit Shetty is also a director of VOKA and a member of GS1.
The Board namely will include 4 new Directors appointed today:
• Ms. Liesbeth Weynants (Independent Director) holds a Master's degree in Law from the
University of Leuven and is specialized in pharmaceutical and regulatory law with a focus on
the life sciences sector. Ms. Weynants has extensive expertise in intellectual property and
patent law for innovative medicines (AbbVie, Allergan, Biogen, Boehringer Ingelheim, Celgene,
J&J, Lundbeck, Merck, Novartis, Sanofi,...). She is currently Managing Partner at the law firm
Hoyng Rokh Monegier and Professor of Intellectual Property Law at the VUB (see resume).
• Ms. An Cloet (Independent Director) holds a Master's degree in Pharmacy from the University
of Leuven and a Degree in Business and Administration from the University of Louvain.
Ms. Cloet has over 25 years of pharmaceutical experience in multiple therapeutic domains, in
particular women's health (contraception, osteoporosis, fertility). She built her career within
MSD, where she has held various positions in Business Development, Marketing and
Corporate Strategy. Ms Cloet is currently External Affairs Director (see resume).
• Ms Amel Tounsi (Non-executive Director) holds a PhD in Biomedical and Pharmaceutical
Sciences from the University of Louvain and has a broad experience in cell-therapy
development. During her career in the biotech sector (Celyad, Texere, Analis, Masthercell), she
acquired a strong expertise in Business Development and Company Development strategy.
She is currently Investment Manager at Noshaq (see resume).
• Ms. Valérie Gordenne (Non-executive Director) holds a Master's degree in Pharmacy from the
University of Liège and has more than 20 years of experience in pharmaceutical Research &
Development, and more specifically in full drug development across a range of therapeutic
areas, in particular in women's health (CSO Mithra, CEO Novalon, General Manager Odyssea
Pharma). She is currently Chief Scientific Officer at Auxin Surgery, CEO of the start-up Odix
and advisor in regulatory affairs.(see resume).
The General Meeting also approved the appointment of Mr. Erik Van Den Eynden (CEO of Straco) as
Independent Director following his cooptation last November, and renewed the mandates of
Mr. Gaëtan Servais (CEO of Noshaq) as Non-executive Director, of Mr. François Fornieri (co-founder of
Mithra) as Non-executive Director and of Mr. Jean-Michel Foidart (co-founder of Mithra and
Permanent Secretary of the Belgian Royal Academy) as Executive Director.
Mr. Stijn Van Rompay, who was expected to join the Board of Directors in November 20201
, has finally
decided to withdraw his application, following the appointment of his father Leon Van Rompay as CEO
in February 2021. In the context of the health crisis, Jean Stéphenne is currently not available to
assume a new board position in addition to his current priority mission within the biotech company
CureVac.
“I am extremely honored to serve as Mithra's next president in this historic year that marks its transition to
a global commercial company ", commented Ajit Shetty. "I would like to thank Mrs. Patricia van Dijck for
her dedication and professionalism during her chairmanship, as well as Mr. Christian Moretti and Mr. Koen
Hoffman who have been key directors to the company's development. We now have a strong and balanced
Board, with directors who are experts in a variety of fields that are essential for the future of the company.
We are determined to deploy the multiple potentialities of Mithra and to support it in the development of its
numerous promising projects ".

quote:

Semper Nescio schreef op 20 mei 2021 17:54:

[...]Telt toch als een koopadvies volgens mij. Ajit kent de wereld, en de wereld kent hem. En Leon zegt aan zijn zoon dat hij nog even geduld moet hebben. Moet er nog zand zijn?

quote:

Kompas schreef op 20 mei 2021 18:22:

[...]

Dat is in elk geval erg veel kennis bij elkaar deze groep mensen en de ambitie straalt er vanaf.

Laat de koersdip nu dan definitief achter ons liggen en vanaf morgen terug richting € 25,- en hoger.

quote:

VP100 schreef op 20 mei 2021 18:51:

Europese goedkeuring. Tweet van Mithra

quote:

Kompas schreef op 20 mei 2021 18:59:

[...]

Exact wat we nu nodig hadden!

quote:

VP100 schreef op 20 mei 2021 19:07:

[...]

Inderdaad, indien het overall sentiment morgen wat meevalt, mag dit ons terug over de 25 tillen!

quote:

Kompas schreef op 20 mei 2021 19:10:

[...]

Het zou eigenlijk te zot voor woorden zijn wanneer, met nu definitief 3 goedkeuringen voor Estelle op zak, dit niet het geval zou zijn.

quote:

VP100 schreef op 20 mei 2021 19:16:

[...]

Ben ook benieuwd of HighBridge weer van een stijging gebruik zal maken om z'n shortpositie uit te breiden of integendeel zal beginnen coveren...

quote:

Kompas schreef op 20 mei 2021 19:28:

[...]

Één ding is zeker. Hopende op een onverwachte EMA afkeuring hoeven ze niet meer uit te breiden of short te blijven zitten. Toch wel erg fijn dat deze EMA goedkeuring nu ook definitief binnen is en alle mogelijke resterende twijfel rondom Estelle naar de prullenbak doet verdwijnen.
Morgen dan maar een stevige opluchtingsrally!

quote:

Catalina schreef op 20 mei 2021 19:40:

[...]

Die highbridge is al een tijdje in een soort hibernation. Ben benieuwd wanneer zij zich weer eens laten gelden. Reken maar dat als zij hun posities moeten gaan coveren dat het hier even flink gaat donderen.